FindTrial
Sign In

A randomized, double-blind study of recombinant human erythropoietin in anemic cancer patients undergoing chemotherapy

A randomized, double-blind study of recombinant human erythropoietin in anemic cancer patients undergoing chemotherapy

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220013
Enrollment
Unknown
Registered
2005-09-01
Start date
2005-09-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anemic cancer patients undergoing chemotherapy

Interventions

investigational material(s) Generic name etc : Recombinant human erythropoietin INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Admini

Sponsors

Chugai Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Anemic cancer patients undergoing chemotherapy

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
The increase in Hb concentration—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026